deamidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Hygroscopic, seal promptly after opening |
| Long-term storage temperature | At or below minus 20 C | Protect from repeated freeze-thaw |
| Working solution stability | Hours when refrigerated | Use within the same working day |
| Primary purity method | Reversed-phase HPLC | Often paired with mass spectrometry |
| Aggregate measurement | Size-exclusion chromatography | Reports high-molecular-weight species |
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
== Potency == Index inducer or just inducer predictably induce metabolism via a given pathway and are commonly used in prospective clinical drug-drug interaction studies. Strong, moderate, and weak inducers are drugs that decreases the AUC of sensitive index substrates of a given metabolic pathway by ≥80%, ≥50% to <80%, and ≥20% to <50%, respectively.
{\displaystyle {\begin{array}{l}{}\\{\ce {^{6}_{4}Be->[5\ {\ce {zs}}]{^{4}_{2}He}+{2_{1}^{1}H}}}\\{\ce {{^{7}_{4}Be}+e^{-}->[53.22\ {\ce {d}}]{^{7}_{3}Li}}}\\{\ce {^{8}_{4}Be->[81.9\ {\ce {as}}]{2_{2}^{4}He}}}\\{\ce {^{10}_{4}Be->[1.387\ {\ce {Ma}}]{^{10}_{5}B}+e^{-}}}\\{\ce {^{11}_{4}Be->[13.76\ {\ce {s}}]{^{11}_{5}B}+e^{-}}}\\{\ce {^{11}_{4}Be->[13.76\ {\ce {s}}]{^{7}_{3}Li}+{^{4}_{2}He}+e^{-}}}\\{\ce {^{12}_{4}Be->[21.46\ {\ce {ms}}]{^{12}_{5}B}+e^{-}}}\\{\ce {^{12}_{4}Be->[21.46\ {\ce {ms}}]{^{11}_{5}B}+{^{1}_{0}n}+e^{-}}}\\{\ce {^{13}_{4}Be->[1\ {\ce {zs}}]{^{12}_{4}Be}+{^{1}_{0}n}}}\\{\ce {^{14}_{4}Be->[4.53\ {\ce {ms}}]{^{13}_{5}B}+{^{1}_{0}n}+e^{-}}}\\{\ce {^{14}_{4}Be->[4.53\ {\ce {ms}}]{^{14}_{5}B}+e^{-}}}\\{\ce {^{14}_{4}Be->[4.53\ {\ce {ms}}]{^{12}_{5}B}+{2_{0}^{1}n}+e^{-}}}\\{\ce {^{15}_{4}Be->[790\ {\ce {ys}}]{^{14}_{4}Be}+{^{1}_{0}n}}}\\{}{\ce {^{16}_{4}Be->[650\ {\ce {ys}}]{^{14}_{4}Be}+{2_{0}^{1}n}}}\\{}\end{array}}}
Insulin aspart, marketed under the brand name Novolog among others, is a modified type of medical insulin used to treat both type 1 and type 2 diabetes. It is typically administered by injection under the skin (into the abdomen, buttocks, thighs, or upper arms), but can also be injected into a vein. Its maximum effect occurs after about 1–3 hours and lasts for 3–5 hours. A biosimilar version of insulin aspart, insulin-aspart-szjj, was released in 2025. Common side effects include low blood sugar, allergic reactions, itchiness, and pain at the injection site. Serious side effects may include low blood potassium. It is generally considered safe to use during pregnancy and breastfeeding. It works similarly to human insulin by enhancing glucose uptake in tissues and reducing glucose production by the liver. It is a synthetic form of human insulin, with a single amino acid change, replacing proline with aspartic acid at the B28 position. Insulin aspart was approved for medical use in the United States in 2000. In 2022, it was the 76th most commonly prescribed medication in the United States, with over 8 million prescriptions. Its production involves yeast that have had the gene for insulin aspart inserted into their genome, allowing the yeast to produce the insulin, which is then harvested from the bioreactor. Insulin aspart is available unbranded from Novo Nordisk.
Sources: en.wikipedia.org
The combination of the beta emitter 177Lu with DOTA-TATE can be used in the treatment of cancers expressing the relevant somatostatin receptors. The U.S. Food and Drug Administration (FDA) considers 177Lu-dotatate to be a first-in-class medication. Alternatives to 177Lu-DOTA-TATE include 90Y (T1/2 = 64.6 h) DOTA-TATE. The longer penetration range in the target tissues of the more energetic beta particles emitted by 90Y (high average beta energy of 0.9336 MeV) could make it more suitable for large tumors while 177Lu would be preferred for smaller volume tumors.
The same procedure was followed as in Annis, but the sample of galaxies used is 80 times larger than that used in the Annis study. Some sources were classified as "lopsided": they appear asymmetric in shape, meaning that one side of the galactic disc is more massive and less luminous than the other. This characteristic, according to Calissendorff, could be an indication that the galaxy is home to a civilization that has placed Dyson spheres in its main part. This can be explained by the fact that the colonization starts from one side of the galactic disk, making it appear darker and leading a distant observer to believe that the core has moved to that same side. On the other hand, a galaxy hosting Dyson spheres should be characterized by a significant source of far-infrared radiation. The fact remains that a Type III civilization can consume energy through a Dyson sphere without surrounding a star. Indeed, such megastructures could also extract energy from a black hole, according to the study by Inoue and Yokoo (2011). However, such a structure would not reduce the luminosity of an observed galaxy. Calissendorff's study concludes that 11 of the sources analyzed (out of a catalog of 2,411 galaxies, or 0.46%) show possible evidence of a Type III civilization. Searching for objects that obscure 90% of the light leaves only one source remains that meets the criteria. These positive sources show a low redshift (so they are old, about 100 million years), which is consistent with possible Type III civilizations, that could have flourished only in the early past.
During the mid-19th century, one of the most remarkable painters was Ramón Torres Méndez, who produced a series of good quality paintings depicting the people and their customs of different Colombian regions. Also noteworthy in the 19th century were Andrés de Santa María, Pedro José Figueroa, Epifanio Garay, Mercedes Delgado Mallarino, José María Espinosa, Ricardo Acevedo Bernal, between many others. More recently, Colombian artists Pedro Nel Gómez and Santiago Martínez Delgado started the Colombian Murial Movement in the 1940s, featuring the neoclassical features of Art Deco. Since the 1950s, the Colombian art started to have a distinctive point of view, reinventing traditional elements under the concepts of the 20th century. Examples of this are the Greiff portraits by Ignacio Gómez Jaramillo, showing what the Colombian art could do with the new techniques applied to typical Colombian themes. Carlos Correa, with his paradigmatic "Naturaleza muerta en silencio" (silent dead nature), combines geometrical abstraction and cubism. Alejandro Obregón is often considered as the father of modern Colombian painting, and one of the most influential artist in this period, due to his originality, the painting of Colombian landscapes with symbolic and expressionist use of animals, (specially the Andean condor). Fernando Botero, Omar Rayo, Enrique Grau, Édgar Negret, David Manzur, Rodrigo Arenas Betancourt, Oscar Murillo, Doris Salcedo and Oscar Muñoz are some of the Colombian artists featured at the international level.
Sources: en.wikipedia.org
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.
Reversed-phase high-performance liquid chromatography is the standard method for purity and related substances. It separates the main peak from deletion sequences and oxidation products. Mass spectrometry is frequently used alongside it to confirm molecular identity.
Aggregates, truncated sequences, and oxidation products receive the most attention. Size-exclusion chromatography covers aggregates, while reversed-phase methods resolve many chemical variants. Limits are set according to the route of administration and the expected exposure.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.